◼ Archived
Health
🔮 fades ✓
CRISPR makes prostate cancer vulnerable to immunotherapy
CRISPR editing turns immune‑cold prostate tumors into immunotherapy targets, sparking a new treatment direction.
Oncology
41 independently checked trend briefs about this subject, newest first.
What this Oncology timeline shows
headlinez.news detected 41 source-qualified news clusters connected to Oncology between June 23, 2026 and July 27, 2026. They span 3 newsroom categories and average 6.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
◼ Archived
Health
🔮 fades ✓
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy
Recent research links the thymus gland and its hormone, thymulin, to reduced age-related inflammation and improved cancer immunotherapy outcomes.
◼ Archived
Business
🔮 fades ✓
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.
◼ Archived
Health
🔮 fades ✓
Leading oncologist reveals 6 habits that could promote longevity and reduce your risk of chronic illness
A leading oncologist is shifting focus from traditional wellness trends toward unconventional longevity habits, including the consumption of ice cream.
◼ Archived
Health
🔮 fades ✗
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood-based mRNA diagnostic test is showing potential in identifying early-stage pancreatic cancer, a condition with historically low survival rates.
◼ Archived
Health
🔮 fades ✓
Creatine supplements may help halt cancer growth, study suggests
Recent research into creatine supplements has prompted conflicting reports regarding their potential impact on cancer growth and immune response.
◼ Archived
Health
🔮 fades ✗
Prostate cancer treatment with fewer side effects 'as effective as radiotherapy and surgery'
New research suggests focal therapy is a viable alternative for prostate cancer, offering similar effectiveness to traditional methods with fewer side effects.
◼ Archived
Health
🔮 fades ✗
Kids with deadliest brain cancers survive years after breakthrough cell therapy
An experimental autologous T cell therapy has led to multi-year survival in children previously diagnosed with terminal brain cancer.
◼ Archived
Health
🔮 holds ✗
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
A new experimental KRAS-targeted vaccine shows promise in early trials for preventing pancreatic cancer in high-risk individuals.
◼ Archived
Health
🔮 holds ✗
Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread
Recent research and medical commentary explore the evolving role of GLP-1 receptor agonists in oncology, sparking debate over their efficacy and risks.
◼ Archived
Health
🔮 fades ✓
A breakthrough in pancreatic cancer has experts excited
Medical experts report promising clinical results for a new pancreatic cancer treatment targeting KRAS-mutated tumors.
◼ Archived
Health
🔮 fades ✓
Second prostate-specific membrane antigen PET scan can change treatment for nearly half of prostate cancer patients
A second PSMA PET scan is influencing treatment paths for nearly half of prostate cancer patients, according to new clinical findings.
◼ Archived
Health
🔮 fades ✓
Maura Gillison, Who Transformed the Treatment of Mouth and Throat Cancers, Dies at 61
The medical community is mourning the death of Maura L. Gillison, a prominent researcher noted for her influence on mouth and throat cancer treatment.
◼ Archived
Business
🔮 fades ✗
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
The FDA has granted approval for Sanofi’s Sarclisa, marking the first time a cancer medication has been cleared for delivery via an on-body injector.
◼ Archived
Technology
🔮 fades ✓
Which ‘AI scientist’ suits your lab? A guide for the perplexed
Anthropic has released a new research workbench, sparking industry discussion on the practical integration of AI tools within laboratory environments.
◼ Archived
Health
🔮 fades ✓
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
Researchers have identified 16 distinct subgroups of acute myeloid leukemia through advanced epigenetic mapping.
◼ Archived
Health
🔮 fades ✗
Painless Swab Detects Oral Cancers in an Hour, With Over 95% Accuracy
A new non-invasive brush biopsy test is making headlines for its ability to detect oral cancers within one hour with over 95% accuracy.
◼ Archived
Health
🔮 fades ✓
Rare transplant gives Stage 4 lung cancer patients a second chance at life
A new study indicates that lung transplants may improve survival outcomes for select patients diagnosed with Stage 4 lung cancer.
◼ Archived
Health
🔮 fades ✓
Aneuploidy selects for the acquisition of driver genes in breast cancer
Researchers identify 90 genes driving basal-like breast cancer, revealing how chromosomal instability promotes the acquisition of disease-linked genetic traits.
◼ Archived
Health
🔮 fades ✗
Largest study yet reveals which cancers have their own microbiomes
Researchers are uncovering the link between tumor microbiomes and cancer treatment efficacy, marking a shift in how oncology approaches immunotherapy.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis has announced a deal to acquire U.K.-based cancer biotech Myricx Bio in a transaction valued at up to $1.5 billion.
◼ Archived
Health
🔮 fades ✓
How a new fungal genome-editing tool could open fresh paths to cancer treatments
Scientists have unlocked a fungal genome-editing tool that could accelerate discovery of new anti-cancer compounds
◼ Archived
Health
🔮 fades ✓
Drug Stops 90% of Pancreatic Cancer Migration in Lab Tests
Researchers have identified a drug capable of inhibiting pancreatic cancer cell migration and triggering self-destruction in laboratory settings.
◼ Archived
Health
🔮 fades ✓
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Emerging research links GLP-1 receptor agonists to potential benefits in cancer prevention and the management of metastatic progression.
◼ Archived
Health
🔮 fades ✗
New screening tool may detect more dangerous prostate cancers than PSA testing alone
Medical reports highlight a potential shift in prostate cancer screening as new tools emerge to supplement traditional PSA testing.
◼ Archived
Health
🔮 fades ✓
Surgeons Warn: Don’t Ignore These Colorectal Cancer Symptoms, No Matter Your Age
Medical experts are urging public vigilance regarding colorectal cancer symptoms as reports highlight an increase in cases among younger demographics.
◼ Archived
Health
🔮 fades ✗
Another B vitamin linked to worse outcomes for cancer - Jacksonville Journal-Courier
New research ties a B vitamin to poorer cancer outcomes, while fatigue and forgetfulness dominate B12 deficiency coverage
◼ Archived
Health
🔮 fades ✓
New vitamin B12 therapy shows promise against deadly brain cancer
A new study indicates that vitamin B therapies may offer potential in the treatment of lethal brain cancers.
◼ Archived
Health
🔮 fades ✓
What went right this week: the good news that matters
HPV vaccine brings cervical cancer deaths to near zero
◼ Archived
Business
🔮 holds ✓
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly’s stock surges as EU panel fast-tracks approvals for two blockbuster drugs, reshaping investor and patient expectations
◼ Archived
Health
🔮 fades ✗
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
Experimental drug daraxonrasib is drawing attention for its performance in clinical trials targeting advanced pancreatic cancer.
◼ Archived
Health
🔮 fades ✗
New blood test detects 90% of aggressive prostate cancer cases, beating current screenings
A new blood test is showing superior results in detecting aggressive prostate cancer compared to standard screening methods.
◼ Archived
Health
🔮 fades ✓
BIO 2026: How a gut feeling transformed cancer treatment forever
Recent reports from BIO 2026 highlight a significant shift in cancer research toward engineered immune cell therapies and specialized engagement strategies.
◼ Archived
Health
🔮 fades ✗
As cancer death rates plunge, clear disparities remain, new report says
A new AACR report finds that while U.S. cancer mortality has dropped significantly since 1991, persistent geographic and racial health disparities remain.
◼ Archived
Health
🔮 fades ✗
Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks
A high-profile cancer therapy study has been retracted by Nature Medicine, prompting discussions regarding international research credibility.
◼ Archived
Health
🔮 fades ✓
A molecule called MHC I was understood for decades as the thing that lets the immune system recognize cancer, until researchers found the immune system attacks hardest exactly when cancer switches it off
Cancer’s immune-evasion trick just got exposed—and it could rewrite treatment strategies
◼ Archived
Health
🔮 fades ✓
Prostate cancer blood test detects twice as many cases
A new blood test could double prostate cancer detection rates, reshaping early screening
◼ Archived
Health
🔮 holds ✓
Seattle scientists seek answers as colorectal cancer trends younger
Researchers are investigating a rise in early-onset colorectal cancer cases, with recent data highlighting connections to demographic and birth-related factors.
◼ Archived
Health
🔮 fades ✓
A blood test that screens for multiple types of cancer? It may be available soon
Advancements in multi-cancer early detection blood tests are sparking debate over their readiness for widespread clinical use.
◼ Archived
Business
🔮 fades ✓
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s experimental lung cancer drug sigvotatug vedotin has failed to meet its primary objective in a late-stage clinical trial.
◼ Archived
Business
🔮 fades ✓
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer’s first drug candidate from its Seagen acquisition, sigvotatug vedotin, failed to meet primary endpoints in a Phase 3 nonsquamous NSCLC trial.